Comparative Activities of Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, Ofloxacin, Sparfloxacin, and Trovafloxacin and Nonquinolones Linozelid, Quinupristin-Dalfopristin, Gentamicin, and Vancomycin against Clinical Isolates of Ciprofloxacin-Resistant and -Susceptible Staphylococcus aureus Strains | Zendy

Mark E. Jones | Zendy; Maarten R. Visser | Zendy; Miriam Klootwijk | Zendy; Peter Heisig | Zendy; J. Verhoef | Zendy; FranzJosef Schmitz | Zendy

Open Access

Comparative Activities of Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, Ofloxacin, Sparfloxacin, and Trovafloxacin and Nonquinolones Linozelid, Quinupristin-Dalfopristin, Gentamicin, and Vancomycin against Clinical Isolates of Ciprofloxacin-Resistant and -Susceptible Staphylococcus aureus Strains

Author(s) -

Mark E. Jones,

Maarten R. Visser,

Miriam Klootwijk,

Peter Heisig,

J. Verhoef,

FranzJosef Schmitz

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.2.421

Subject(s) - trovafloxacin , sparfloxacin , moxifloxacin , levofloxacin , quinupristin , dalfopristin , ofloxacin , microbiology and biotechnology , vancomycin , ciprofloxacin , gentamicin , medicine , pefloxacin , antibacterial agent , antibiotics , staphylococcus aureus , biology , genetics , bacteria

The activities of eight fluoroquinolones and linezolid, quinupristin-dalfopristin (Synercid), gentamicin, and vancomycin were tested against 96 ciprofloxacin-susceptible and 205 ciprofloxacin-resistantStaphylococcus aureus strains. Overall, clinafloxacin, followed by moxifloxacin and trovafloxacin, was the most active quinolone tested. For all isolates, linezolid and quinupristin-dalfopristin showed activities that were at least comparable to vancomycin, with no cross-resistance to any other test compound.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research